<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05065073</url>
  </required_header>
  <id_info>
    <org_study_id>GE OCT</org_study_id>
    <nct_id>NCT05065073</nct_id>
  </id_info>
  <brief_title>Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography</brief_title>
  <acronym>GE OCT</acronym>
  <official_title>Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Minneapolis Heart Institute Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Minneapolis Heart Institute Foundation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed study aims to compare (a) volume contrast administered for Optical Coherence&#xD;
      Tomography (OCT) Imaging, (b) length of clear OCT images, and (c) electrocardiographic&#xD;
      changes immediately after contrast injection between iso-osmolar and low-osmolar contrast&#xD;
      agents. The proposed study is a prospective, single-centered, randomized controlled, study&#xD;
      that will compare an iso-osmolar vs. a low-osmolar contrast agent in patients undergoing&#xD;
      clinically indicated coronary OCT imaging. Each patient will be randomized to OCT&#xD;
      acquisition.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients referred to the Cardiac Catheterization laboratory for clinically indicated coronary&#xD;
      angiography and coronary OCT imaging will be identified by a study team member and screened&#xD;
      for eligibility. The proposed study is a prospective, single-center, randomized, controlled,&#xD;
      study that will compare an iso-osmolar vs a low-osmolar contrast agent in patients undergoing&#xD;
      clinically-indicated coronary OCT imaging. Each patient will be randomized to OCT&#xD;
      acquisition. Eligible patients will be approached to obtain informed consent by a member of&#xD;
      the study team. Once consent is obtained and inclusion and exclusion criteria are verified,&#xD;
      patients are randomized to undergoing OCT image acquisition with iso-osmolar contrast&#xD;
      media(IOCM) first or with low-osmolar contrast media first (LOCM).&#xD;
&#xD;
      Then the patients undergo coronary angiography and OCT imaging as per clinical standard of&#xD;
      care. However, during the OCT imaging acquisition based on their randomization assignment the&#xD;
      patient will undergo the 1st OCT imaging run with either iso-osmolar contrast media or with&#xD;
      low-osmolar contrast media. Following this a 2nd OCT imaging run of the same coronary vessel&#xD;
      will be done using the other contrast media that was not used during the first run.&#xD;
      Therefore, each patient will serve as a comparator to themselves, but also to each other. The&#xD;
      electrocardiogram will be recorded during and for 30 seconds after each injection and&#xD;
      analyzed offline for detection of any changes&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 30, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Randomized, controlled study. Each patient will be randomized to undergoing OCT image acquisition with iso-osmolar contrast media first, or with low-osmolar contrast media first. Following this will be a second OCT image acquisition of the same coronary vessel with the other contrast media. Thus, each patient will serve as comparator to themselves, and to each other</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Contrast Volume after Injection</measure>
    <time_frame>30 seconds after injection</time_frame>
    <description>Contrast volume will be measured after each injection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clear OCT Images</measure>
    <time_frame>Intra-operative</time_frame>
    <description>Length of clear OCT images will be defined as visible lumen border &gt;270 degrees</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiographic (ECG) Changes</measure>
    <time_frame>During and 30 seconds after injection</time_frame>
    <description>Electrocardiographic(ECG) changes will be assessed during and for a period of 30 seconds after each injection of contrast for OCT, to detect and quantify any of the following abnormalities: arrhythmias, mean axis deviation and QRS enlargement (type A abnormalities); and ventricular repolarization (ST/T) changes (type B abnormalities)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Contrast Media Reaction</condition>
  <arm_group>
    <arm_group_label>Iso-Osmolar Contrast Media</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Will receive iso-osmolar media first, low-osmolar media second</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-Osmolar Contrast Media</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Will receive low-osmolar media first, iso-osmolar media second</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iodixanol</intervention_name>
    <description>Iso-osmolar Contrast Media</description>
    <arm_group_label>Iso-Osmolar Contrast Media</arm_group_label>
    <arm_group_label>Low-Osmolar Contrast Media</arm_group_label>
    <other_name>Visipaque</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iohexol</intervention_name>
    <description>Low-Osmolar Contrast Media</description>
    <arm_group_label>Iso-Osmolar Contrast Media</arm_group_label>
    <arm_group_label>Low-Osmolar Contrast Media</arm_group_label>
    <other_name>Omnipaque</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 years or greater&#xD;
&#xD;
          2. Willing and able to give informed consent. The patients must be able to comply with&#xD;
             study procedures&#xD;
&#xD;
          3. Undergoing clinically-indicated coronary angiography and OCT&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Baseline electrocardiographic changes hindering interpretation (such as left&#xD;
             bundle-branch block, and &gt;1 mm ST segment depression)&#xD;
&#xD;
          2. Emergency cardiac catheterization (for example in patients with ST-segment elevation&#xD;
             acute myocardial infarction)&#xD;
&#xD;
          3. Inability to provide symptomatic assessment&#xD;
&#xD;
          4. Known allergy to contrast&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emmanouil Brilakis, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Minneapolis Heart Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bavana Rangan, BDS, MPH</last_name>
    <phone>817-821-9945</phone>
    <email>bavana.rangan@allina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Minneapolis Heart Institute Foundation</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bavana V Rangan, BDS, MPH</last_name>
      <phone>817-821-9945</phone>
      <email>bavana.rangan@allina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 14, 2021</study_first_submitted>
  <study_first_submitted_qc>September 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2021</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Optical Coherence Tomography</keyword>
  <keyword>Contrast Agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

